Vanguard Global Advisers
PRCT icon

Vanguard Global Advisers’s Procept Biorobotics PRCT Stock Holding History

Vanguard Global Advisers’s Portfolio PRCT Stock Details PRCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$503K Sell
22,278
-21
-0.1% -$526 ﹤0.01% 2104
2026
Q1 		$558K Buy
+22,299
New +$628K ﹤0.01% 1987

Other funds holding PRCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Global Advisers's PRCT Position: Q2 2026 in Review

Vanguard Global Advisers reduced its Procept Biorobotics (PRCT) stake by 0.09% in Q2 2026, selling an estimated $526 and leaving 22,278 shares worth $503K. The position accounts for ﹤0.01% of the portfolio, ranked #2104.

Vanguard Global Advisers first reported a position in PRCT in Q1 2026 and has held it in 2 quarters since. The position peaked at $558K in Q1 2026. 252 funds tracked by Wall St. Rank hold PRCT as of Q2 2026.

  • Vanguard Global Advisers held 22,278 shares of Procept Biorobotics worth $503K as of Q2 2026.
  • Vanguard Global Advisers sold 21 Procept Biorobotics shares in Q2 2026, an estimated $526.
  • Procept Biorobotics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2104 holding.
  • Vanguard Global Advisers first reported a position in Procept Biorobotics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Global Advisers's Procept Biorobotics position peaked at $558K in Q1 2026.
  • 252 funds tracked by Wall St. Rank held Procept Biorobotics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.